Return to search

Rekombinantní vakcíny proti solidním a hematologickým nádorům: vývoj a stanovení jejich účinnosti / Recombinant vaccines against solid and hematological cancer: development and monitoring of vaccines-induced immunity

K. Babiarová Ph.D. Thesis ABSTRACT Cancer immunotherapy is concerned generally with the activation of cancer immunity specific for tumor antigens (TA) produced by cancer cells. My PhD thesis focused on the development of different types of cancer vaccines expressing various TA and predominantly on the determination of the efficacy of these vaccines. For studying TA-specific cancer cellular immunity in mice immunized with these vaccines, I used mainly the ELISPOT-IFNγ assay. First, DNA, recombinant vaccinia virus (rVACV) and peptide vaccines against WT1 positive tumors were prepared. They consist of a fragment of WT1 protein with motifs predicted to bind to Db murine MHC class I. The administration of peptide vaccines by tattoo delivery in combination with unmethylated CpG motifs and anti-TGFβ monoclonal antibody was the most effective. Next, I was interested in the immunotherapy of chronic myeloid leukemia (CML). Hruskova et al. prepared the mouse polyomavirus-like particles (MPyV-VLP) carrying the junction region of BCR-ABL fusion protein (1). In our laboratory, there were constructed the other types of CML vaccines with the expression of the junction region of BCR-ABL fusion protein, such as DNA or rVACV, too. Prepared vaccines failed to induce effective cancer immune response. It seems that BCR-ABL...

Identiferoai:union.ndltd.org:nusl.cz/oai:invenio.nusl.cz:327445
Date January 2013
CreatorsBabiarová, Katarína
ContributorsNěmečková, Šárka, Říhová, Blanka, Mikyšková, Romana
Source SetsCzech ETDs
LanguageCzech
Detected LanguageEnglish
Typeinfo:eu-repo/semantics/doctoralThesis
Rightsinfo:eu-repo/semantics/restrictedAccess

Page generated in 0.0023 seconds